Product Information
Equetro (Extended Release Carbamazepine) has received FDA approval for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder. Equetro (Extended Release Carbamazepine Capsules) has been shown to significantly reduce manic symptoms in bipolar patients with manic and mixed episodes.Bipolar Disorder is characterized by episodes of mania and depression, with periods of normal mood in between. The disorder can have devastating effects on an individual's life, although proper diagnosis and early treatment can usually alter the course of the illness.
The most frequently reported side effects with Equetro (Extended Release Carbamazepine) were dizziness, drowsiness, unsteadiness, nausea and vomiting.
Initiating therapy at the lowest possible effective dose can minimize adverse events that are associated with taking Equetro (Extended Release Carbamazepine). Reports of transient or persistent decreased platelet or white blood cell count are not uncommon in association with the use of Equetro (Extended Release Carbamazepine).
Although the vast majority of cases of leukopenia have not progressed to the more serious conditions of aplastic anemia or agranulocytosis, complete pretreatment hematological testing should be obtained as a baseline. Patients should be monitored and discontinuation of Equetro (Extended Release Carbamazepine Capsules) should be considered if any evidence of bone marrow depression occurs. Because the possibility of a suicide attempt is inherent in bipolar disorder, close supervision of high-risk patients should accompany drug therapy.
Equetro (Extended Release Carbamazepine Capsules) was approved by the Food & Drug Administration in December 2004 for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder. Equetro (Extended Release Carbamazepine) is available in 100 milligram (mg), 200 mg and 300 mg dosage strengths.
Buy Equetro (Carbamazepine) at the lowest prices from our pharmacy located in British Columbia Canada.
